Due to the continuous variation of the new coronavirus and the high demand for nucleic acid testing, TANBead (6797) reported sales of NT$140 millio in August, a monthly growth of 11% and an increasing for two successive months, and the cumulative sales of NT$1.38 billion for the period from January to August, an annual growth of 124%.
Continuously developing its product line, TANBead will attend the 73rd American Association for Clinical Chemistry AACC from September 26th to September 30th. In addition to the Maelstrom 4800, TANBead will also showcase its new product, Switch 8, in a move to enter the US$1.52 billion global scientific research market and to complete its product line of nucleic acid extraction instruments.
According to the research data of BIS Research, the scientific research market (Research Use Only RUO) has a scale of about US$730 million, which is the application market with the highest ratio in the global nucleic acid extraction market, much higher than the second largest medical testing market of US$340 million.
It is expected that the research expenses of Academic Research Centers will grow from US$730 million in 2020 to US$1.52 billion in 2031, with a compound annual growth rate of 6.85%.
In addition to completing the company's nucleic acid extraction instrument product line, the launch of the new Switch 8 will expand the company's scope into the most prospective nucleic acid extraction market, maintaining the company's growing.
TANBead’s operation performance was outstanding, with net profit of NT$396 million in the first half of the year, a significant growth of 382.85%.
TANBead stated that the company has been actively cultivating the global market, with stable development in Europe, the U.S. and Korea. The recent severe epidemic in Southeast Asia has led to a significant increase in shipments from Vietnam, Thailand, Indonesia and other Southeast Asian countries, as well as winning many large-scale hospital bids, which has contributed to the growth of revenues.
